ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs MXN
18.116
-0.06%
Brent Oil
84.475
0.34%
Bitcoin
61,695.29
-0.19%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Freeline Therapeutics Holdings PLC (FRLN)

  7. Freeline Therapeutics Holdings PLC (FRLN) Noticias

FRLN

Freeline Therapeutics (FRLN)

Freeline Therapeutics Holdings PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:FRLN
FechaHoraFuenteTítuloSímboloCompañía
24/04/202415:00GlobeNewswire Inc.Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202415:38Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202415:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202414:22Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202406:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202406:00GlobeNewswire Inc.Acquisition of Freeline by Syncona Becomes EffectiveNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/02/202411:00GlobeNewswire Inc.Freeline Shareholders Approve Acquisition by SynconaNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/12/202316:21Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/11/202306:30GlobeNewswire Inc.Syncona to Acquire Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/10/202301:01GlobeNewswire Inc.Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
16/10/202306:00GlobeNewswire Inc.Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/10/202306:00GlobeNewswire Inc.Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
15/08/202306:00GlobeNewswire Inc.Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/08/202306:30GlobeNewswire Inc.Freeline Therapeutics to Host Second Quarter 2023 Financial Results CallNASDAQ:FRLNFreeline Therapeutics Holdings PLC
31/07/202306:30GlobeNewswire Inc.Freeline to Participate in Upcoming Investor ConferencesNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/07/202306:30GlobeNewswire Inc.Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
26/06/202306:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
26/06/202306:30GlobeNewswire Inc.Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/06/202307:00GlobeNewswire Inc.Freeline to Present at 2023 Jefferies Healthcare ConferenceNASDAQ:FRLNFreeline Therapeutics Holdings PLC
30/05/202306:30GlobeNewswire Inc.Freeline Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/05/202307:00GlobeNewswire Inc.Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/05/202307:05GlobeNewswire Inc.Freeline Completes ADS Ratio ChangeNASDAQ:FRLNFreeline Therapeutics Holdings PLC
21/04/202307:54Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
21/04/202306:00GlobeNewswire Inc.Freeline Announces Proposed ADS Ratio ChangeNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/04/202307:00GlobeNewswire Inc.Freeline to Present at 22nd Annual Needham Virtual Healthcare ConferenceNASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/04/202306:03Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/04/202306:00GlobeNewswire Inc.Freeline Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:FRLNFreeline Therapeutics Holdings PLC
28/03/202306:00GlobeNewswire Inc.Freeline Therapeutics to Host Full Year 2022 Financial Results CallNASDAQ:FRLNFreeline Therapeutics Holdings PLC
14/02/202312:55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:FRLN

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
USOTC
ADDYY
Adidas (QX)
NYSE
AXP
American Express
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
COIN
BTCUSD
Bitcoin
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
CCOM
US500
US 500
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados